Assetmark Inc. Has $5.32 Million Holdings in argenx SE (NASDAQ:ARGX)

Assetmark Inc. raised its position in argenx SE (NASDAQ:ARGX) by 11.3% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 8,648 shares of the company’s stock after acquiring an additional 879 shares during the period. Assetmark Inc.’s holdings in argenx were worth $5,319,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Stifel Financial Corp lifted its holdings in shares of argenx by 15.3% in the third quarter. Stifel Financial Corp now owns 8,832 shares of the company’s stock valued at $4,788,000 after purchasing an additional 1,170 shares in the last quarter. FMR LLC lifted its holdings in shares of argenx by 35.9% in the third quarter. FMR LLC now owns 4,793,472 shares of the company’s stock valued at $2,598,445,000 after purchasing an additional 1,265,486 shares in the last quarter. Simplify Asset Management Inc. lifted its holdings in shares of argenx by 64.0% in the third quarter. Simplify Asset Management Inc. now owns 2,419 shares of the company’s stock valued at $1,311,000 after purchasing an additional 944 shares in the last quarter. Stephens Inc. AR bought a new position in shares of argenx in the fourth quarter valued at approximately $310,000. Finally, Ritholtz Wealth Management lifted its holdings in shares of argenx by 85.5% in the fourth quarter. Ritholtz Wealth Management now owns 898 shares of the company’s stock valued at $552,000 after purchasing an additional 414 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on ARGX shares. Wells Fargo & Company raised their target price on argenx from $723.00 to $741.00 and gave the company an “overweight” rating in a report on Friday, February 28th. Oppenheimer raised their target price on argenx from $675.00 to $704.00 and gave the company an “outperform” rating in a report on Friday, February 28th. Wedbush reiterated an “outperform” rating and set a $655.00 price target on shares of argenx in a report on Tuesday, December 3rd. Piper Sandler lifted their price target on argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a report on Tuesday, January 7th. Finally, William Blair reiterated an “outperform” rating on shares of argenx in a report on Friday, February 28th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $662.83.

argenx Price Performance

NASDAQ:ARGX opened at $594.21 on Friday. The business has a fifty day simple moving average of $641.45 and a two-hundred day simple moving average of $594.00. argenx SE has a 1 year low of $349.86 and a 1 year high of $678.21. The company has a market capitalization of $36.10 billion, a P/E ratio of -675.24 and a beta of 0.59.

argenx (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.60. The company had revenue of $761.22 million during the quarter, compared to analysts’ expectations of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. As a group, analysts anticipate that argenx SE will post 3.13 earnings per share for the current year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.